Your partner in oncology


Oncology Therapeutic Development

100 rue Martre
92110 Clichy - FRANCE
Tel:  +33 1 47 15 01 01
Fax: +33 1 45 19 06 59

Contact Us

About us

Founded in 2005 by Prof. Esteban Cvitkovic, Oncology Therapeutic Development (OTD) is a Paris-based small-scale CRO spin-off from a previous oncology-specialist CRO, Cvitkovic & Associates Consultants, established by Prof. Cvitkovic in 1996.

The two major axes of our small and highly experienced team overseen by Prof. Cvitkovic, are the Clinical Group including medical oncologists, project managers, CRAs, and a Preclinical Group of scientists, both of which are supported by medical writing and support staff.

We also perform pharmacovigilance and quality assurance tasks, and the team is completed by long-standing collaborations with data management, statistics, pharmacokinetics and pharmacodynamics groups, as well as regulatory experts.

Our strength lies in our diverse backgrounds, extensive oncology experience and high-level training. Team members (all MD, PhD or MSc) have solid experience in preclinical and clinical oncology, working with small biotech companies, mid-size and large pharmaceutical organizations, hospitals and CROs, ensuring an extensive network worldwide.


Management Team

Esteban CVITKOVIC, MD, OTD Founder and Head of Consulting. A medical oncologist specialized in solid tumors and drug development, Prof. Cvitkovic has been instrumental in defining the clinical utility of several oncology drugs contributing to their registration including cisplatin, oxaliplatin, vindesine, bleomycin, vinorelbine, amifostine, irinotecan, docetaxel and trabectedin. He was also responsible for leading therapeutic advances in germ cell tumors, squamous head and neck cancer, EBV-related nasopharyngeal carcinoma, soft tissue sarcomas and gastrointestinal cancers.

Prof. Cvitkovic has more than thirty years of international experience in oncology therapeutics, including hands-on clinical research and clinical pharmacology for developing single-agent and combination regimens, performing disease-oriented therapeutic impact assessment, as well as evaluating novel agents in preclinical development and optimizing their clinical efficacy.

He has authored more than 200 peer-reviewed articles and 600 abstracts focused on therapeutic oncology development. His international career, which started in Argentina where he graduated as the world's youngest physician at the age of 19 years, includes staff and academic appointments at Memorial Sloan Kettering Cancer Center (New York, US), Columbia Presbyterian (New York, US), Instituto Mario Negri (Milan, Italy), Institut Gustave Roussy (Villejuif, France), Hôpital Paul Brousse (Villejuif, France) and Hôpital Saint-Louis (Paris, France). Prof. Cvitkovic founded the oncology-focused CRO Cvitkovic & Associates Consultants, S.A. (CAC) in 1996 which was sold to AAIPharma in 2006.


Mohamed BEKRADDA, MD, Senior Medical Director. Dr. Bekradda is a board-certified medical oncologist with 28 years of experience in clinical development of anticancer drugs in Phase I, II and III trials. His professional career has focused on genitourinary and gastrointestinal cancers. Highlights include therapeutic evaluation in hormone-resistant prostate cancer, development of cisplatin-containing chemotherapy regimens for treatment of non-seminomatous germ cell tumors and development of oxaliplatin-containing regimens of colorectal cancer and non-small cell lung cancer. He has worked with a range of agents, including docetaxel, oxaliplatin, alemtuzumab, capecitabine, trastuzumab and advexin. He has also led teams of medical oncologists conducting onsite reviews for large international compassionate-use cohorts.

Dr. Bekradda has held academic and staff appointments at Institut Gustave Roussy (Villejuif, France), Centre Léon Bérard (Lyon, France) and the Center Hospitalier Sud Francilien (Essonnes, France). In 1996, he cofounded CAC with Prof. Cvitkovic. Prior to joining OTD, Dr. Bekradda worked at Hoffmann-La Roche Ltd.


Carmen KAHATT, MD, Senior Medical Leader. Dr. Kahatt is a board-certified medical oncologist with 17 years of experience in clinical development of anticancer drugs in Phase I, II and III trials. Her professional career has focused on early development, including preclinical translational studies to Phase II. Highlights include several first-in-man studies, including with first-in-class drugs. Dr Kahatt has worked with a range of agents, notably cytotoxics and small molecules. She has also participated in the preparation of IND, IMPD, pre-NDA, packages for health authorities. She also has experience in management of medical oncologists and medical writing teams.

Dr. Kahatt has held academic and staff appointments at National institute of Cancer (Lima-Peru), Social Security Hospital, (Lima-Peru) and Paul Brousse Hospital (Villejuif, France). In 2001, she joined the CRO Cvitkovic & Associés Consultants (CAC, France) with Prof. Cvitkovic, then move to Novartis (Basel). Prior to joining OTD, Dr. Kahatt was Head of Oncology at Pharmamar (Spain).


Maria Eugenia RIVEIRO, PhD, Preclinical Research Manager. Dr Riveiro obtained an honors degree in biochemistry at Buenos Aires University, Argentina and was then awarded a Bunge & Born Foundation scholarship for oncology research leading to an internship at Ghent University, Belgium. She obtained her PhD in Pharmacology at the Buenos Aires University then took up a postdoctoral fellowship from the National Council of Research of Argentina.

Dr. Riveiro has authored more than 22 peer-reviewed articles and 70 abstracts in oncology drug development and cell signal transduction. With over ten years’ experience in preclinical drug development in hematologic and solid tumors models, she has experience in organic and medicinal chemistry, molecular biology, high-throughput screening of new leads as well as in vivo pharmacological studies with small animals.


Fabrice BOURDEL, MScSenior Project Manager. Fabrice Bourdel has an honors degree in biology (biology and pharmacology of ageing) and an MSc in cellular and molecular biology. With over ten years’ experience in clinical oncology research from working at the oncology-specialized CRO Cvitkovic and Associates Consultants (CAC) and subsequently with AAIPharma, he has managed more than 20 clinical trials, covering phase I through international phase IV studies, with particular expertise in phase I oncology trials.


Nicolas LACHAUX, MSc, Senior Project Manager. Nicolas Lachaux has an MSc in molecular and cellular biology. He has seven years clinical research experience, working with the oncology CRO Cvitkovic and Associates Consultants (CAC) and subsequently with AAIPharma. His experience includes project management, CRA manager, business development, and SOP preparation. He also has extensive experience in CRA training, including the preparation and implementation of training programs.


Beatrice Houy, MSc, Overall Project Manager. Beatrice obtained her Masters I in Neurosciences from University Aix-Marseille I and her Masters II in Clinical and Pathologic Psychology with a specialization in Neurology from the University René Descartes of Paris. In 2014, she obtained a University Diploma of Quality Auditor in the Pharmaceutical Industry at University René Descartes of Paris.

She joined OTD in July 2012 and is responsible for overall project management, ensuring the timely execution of project objectives, Sponsor reporting, CRA recruitment and training. She is also OTD’s Quality Manager, for internal reviews and site audits.

Prior to joining OTD, Béatrice Houy was project manager in a non-profit organization specialized in gynaecological cancer, and in AAI Pharma, formerly Cvitkovic and Associates Consultants (CAC). In both positions she managed international clinical studies of anti-cancer drugs (phases I, II and III) in a range of indications. Prior to this, Béatrice was a Clinical Research Associate in a number of CROs, performing monitoring of clinical studies in neurology as wellas gastroenterology, ophthalmology and pneumology.